Diabetes insipidus

43,496views

Diabetes insipidus

ICS

ICS

Bacterial structure and functions
Staphylococcus aureus
Staphylococcus epidermidis
Streptococcus pneumoniae
Streptococcus pyogenes (Group A Strep)
Streptococcus agalactiae (Group B Strep)
Clostridium perfringens
Clostridium botulinum (Botulism)
Bacillus cereus (Food poisoning)
Corynebacterium diphtheriae (Diphtheria)
Listeria monocytogenes
Escherichia coli
Shigella
Legionella pneumophila (Legionnaires disease and Pontiac fever)
Yersinia pestis (Plague)
Helicobacter pylori
Neisseria meningitidis
Neisseria gonorrhoeae
Bordetella pertussis (Whooping cough)
Haemophilus influenzae
Mycobacterium tuberculosis (Tuberculosis)
Chlamydia trachomatis
Borrelia burgdorferi (Lyme disease)
Treponema pallidum (Syphilis)
Rickettsia rickettsii (Rocky Mountain spotted fever) and other Rickettsia species
Viral structure and functions
Varicella zoster virus
Cytomegalovirus
Epstein-Barr virus (Infectious mononucleosis)
Human herpesvirus 8 (Kaposi sarcoma)
Herpes simplex virus
Human herpesvirus 6 (Roseola)
Adenovirus
Parvovirus B19
Human papillomavirus
Poxvirus (Smallpox and Molluscum contagiosum)
Poliovirus
Rhinovirus
Influenza virus
Mumps virus
Respiratory syncytial virus
Measles virus
Human parainfluenza viruses
Zika virus
West Nile virus
Norovirus
Rotavirus
Coronaviruses
HIV (AIDS)
Rabies virus
Rubella virus
Histoplasmosis
Candida
Aspergillus fumigatus
Cryptococcus neoformans
Plasmodium species (Malaria)
Babesia
Cryptosporidium
Toxoplasma gondii (Toxoplasmosis)
Enterobius vermicularis (Pinworm)
Cell wall synthesis inhibitors: Penicillins
Cell wall synthesis inhibitors: Cephalosporins
DNA synthesis inhibitors: Fluoroquinolones
Pediatric infectious rashes: Clinical
Reye syndrome
Skin cancer: Clinical
Environmental and chemical toxicities: Pathology review
Paracetamol toxicity
Hyperthyroidism: Pathology review
Hyperthyroidism: Clinical
Thyroid nodules and thyroid cancer: Clinical
Herpesvirus medications
Lower urinary tract infection
Urinary tract infections: Pathology review
Urinary tract infections: Clinical
Kidney stones
Renal failure: Pathology review
Diabetes insipidus
Endocrine system anatomy and physiology
Hypopituitarism
Hypertension
Adrenal masses: Pathology review
Blood components
Testosterone
Anemia of chronic disease
Systemic lupus erythematosus (SLE): Clinical
Diarrhea: Clinical
Joint pain: Clinical
Rheumatoid arthritis: Clinical
Chronic kidney disease: Clinical
Diabetes mellitus: Clinical
Diabetic nephropathy
Blistering skin disorders: Clinical
Sexually transmitted infections: Clinical
Pneumonia: Clinical
Pneumonia: Pathology review
Nitrogen and urea cycle
Diabetes mellitus: Pathology review
Viral exanthems of childhood: Pathology review
Cardiac preload
Cardiac afterload
Miscellaneous genetic disorders: Pathology review
Mendelian genetics and punnett squares
Gel electrophoresis and genetic testing

Flashcards

Diabetes insipidus

0 of 6 complete

Questions

USMLE® Step 1 style questions USMLE

0 of 2 complete

A 21-year-old woman presents to the clinic because of increased thirst and urination. Her symptoms started gradually around 2 months ago. Past medical history is notable for cystic acne. She was started on demeclocycline in the last appointment 3 months ago. Review of systems is otherwise unremarkable. Vitals are within normal limits. Physical examination shows facial acne that has improved from the last visit. Laboratory studies are as follows:  
 Laboratory value  Result  Reference Range 
 Serum osmolality  300 mOsm/kg  275-295 mOsm/kg 
 Urine osmolality  195 mOsm/kg  50-1,400 mOsm/kg 
 2 hours after a trial of synthetic ADH administration  
 Serum osmolality  305 mOsm/kg  275-295 mOsm/kg 
 Urine osmolality  201 mOsm/kg  50-1,400 mOsm/kg 
   
The patient is provided hydrochlorathiazide for treatment of her condition, instructed to discontinue demeclocycline, and encouraged to follow a low-sodium, low-protein diet. Which of the following best describes the rationale for treatment with hydrochlorathiazide?  

Transcript

Watch video only

With diabetes insipidus, “diabetes” means an increased passing of urine, and “insipidus” means tasteless; so diabetes insipidus is a condition characterized by the production of large quantities of dilute and tasteless urine.

The tasteless urine of diabetes insipidus distinguishes it from diabetes mellitus which describes sweet tasting urine- and, yes, urine was really tasted at one point in time to make that distinction!

Now, in the brain there’s a region called the hypothalamus.

Inside the hypothalamus are osmoreceptors, which can sense the osmolality of the blood, or how concentrated it is.

Osmolality is the concentration of dissolved particles in the blood plasma, or the liquid portion of blood.

There are a number of dissolved particles in the blood plasma, but the major ones are glucose, sodium, and blood urea nitrogen, and a normal osmolality is between 285 and 295 milli Osmoles per kilogram.

During periods of dehydration there is an increase in concentration of these particles in the blood and osmolality increases.

The osmoreceptors in the hypothalamus detect the increased osmolality and that triggers the sensation of thirst, which tells us to drink more water. The water then gets absorbed and dilutes the blood, bringing the osmolality back to normal.

In addition to osmoreceptors, the hypothalamus also contains a cluster of neurons that are found in a specific spot called the supraoptic nucleus.

These neurons produce a hormone called antidiuretic hormone, or ADH. ADH is also called vasopressin because it causes smooth muscle around the blood vessels to contract, which increases blood resistance and raises blood pressure.

When the osmoreceptors detect high osmolality, they signal the supraoptic nucleus to send ADH down the supraoptico-hypophyseal tract, which runs through the infundibulum or pituitary stalk, and into the posterior pituitary gland, where it is then released into the blood.

ADH travels to the kidneys, specifically to the distal convoluted tubule and collecting ducts of the nephrons and binds to a receptor called vasopressin receptor 2, or AVPR2.

When AVPR2 is bound, proteins called aquaporins, which usually sit in vesicles inside the cells of the distal convoluted tubule and collecting ducts, start to embed themselves in the apical surface of the cells, which is the side facing the lumen of the tubule.

These aquaporins ultimately allow water -- and only water -- to travel out of the lumen of the tubule and into the cells lining the nephron, and ultimately back into the blood. Just like drinking more water, this dilutes the blood, and returns plasma osmolality to a normal level.

However, this reabsorption process also decides how much water leaves the body as urine, and how concentrated the urine is, which is one of the things that keeps a normal urine osmolality between 300 and 900 milli Osmoles per kilogram.

Diabetes insipidus is when the kidneys reabsorb too little water from the lumen of the tubule, causing the body to produce unusually large quantities of urine, which is called polyuria.

Since there’s less water in the blood, plasma osmolality increases and that triggers thirst and causes an individual to drink a lot, which is called polydipsia.

There are four types of diabetes insipidus, each with its own underlying cause.

The first type is central diabetes insipidus, which is when there’s a problem in the hypothalamus or pituitary gland preventing ADH production or release. As a result, there’s insufficient ADH in the blood, and that means there is less vasoconstriction, and that there are insufficient aquaporins in the kidneys.

Central diabetes insipidus is often caused by damage to the hypothalamus osmoreceptors, the supraoptic nucleus, or the supraoptico-hypophysial tract, but in other cases, the exact cause is hard to identify.

The second type is nephrogenic diabetes insipidus, which is when there’s a problem with the kidneys themselves, which makes them unresponsive to ADH. That can happen due to a genetic defect which can lead to abnormal vasopressin receptors or aquaporin proteins that are unresponsive to ADH.

In addition, there are medications like lithium that can decrease the production of aquaporin proteins in the collecting duct.

Finally, there are kidney disorders like polycystic kidney disease that can cause diabetes insipidus.

The third type is gestational diabetes insipidus, which occurs when the placenta of a pregnant woman releases an enzyme called vasopressinase that breaks down vasopressin or ADH. As a result, ADH might still be produced and released as normal, but it doesn’t get to exert its full effect on the blood vessels or kidneys.

In women with gestational diabetes insipidus, vasopressinase is produced starting in week 8 of pregnancy, and peaks in the third trimester. As a result, the symptoms typically worsen during the course of the pregnancy right up until birth when the placenta is removed, but can continue for up to two months after birth due to residual vasopressinase.

Key Takeaways

Diabetes insipidus is when the body cannot regulate its fluid levels properly and loses a lot of water in the urine. There are two major types of diabetes insipidus, which are central and nephrogenic diabetes insipidus. Central diabetes insipidus occurs when the hypothalamus is not producing enough antidiuretic hormone (ADH). ADH ensures that the kidneys produce less urine and reduce water loss. On the other hand, nephrogenic diabetes insipidus results from the kidneys failing to respond to ADH. People with diabetes insipidus present with excessive quantities of diluted urine (polyuria), resulting in excessive thirst (polydipsia).

Sources

  1. "Robbins Basic Pathology" Elsevier (2017)
  2. "Harrison's Principles of Internal Medicine, Twentieth Edition (Vol.1 & Vol.2)" McGraw-Hill Education / Medical (2018)
  3. "Pathophysiology of Disease: An Introduction to Clinical Medicine 8E" McGraw-Hill Education / Medical (2018)
  4. "CURRENT Medical Diagnosis and Treatment 2020" McGraw-Hill Education / Medical (2019)
  5. "Harrison's Endocrinology, 4E" McGraw-Hill Education / Medical (2016)
  6. "THE PATHOGENESIS OF DIABETES INSIPIDUS." Journal of the American Medical Association (1907)
  7. "Management of Hypopituitarism" Journal of Clinical Medicine (2019)
  8. "Post-Traumatic Hypopituitarism—Who Should Be Screened, When, and How?" Frontiers in Endocrinology (2018)